So far, immunotherapies based on immune checkpoint inhibitors have not been specifically proposed for apocrine carcinomas, due to the low level or absent expression of PD-L1, in contrast to BC with triple negative phenotype, which is known to be variably PD-L1 positive (9–59%) [46, 49]. The gene discussed is CD274; the disease is breast cancer.